Cargando…
Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth facto...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3588609/ https://www.ncbi.nlm.nih.gov/pubmed/23467578 http://dx.doi.org/10.2147/BTT.S25862 |